Form 4: 10x Genomics Director Receives RSU Grant
Director Equity Grant
Director Shehnaaz Suliman was granted 8,829 restricted stock units as part of her compensation package with 10x Genomics.
Summary
- Director Shehnaaz Suliman acquired 8,829 restricted stock units (RSUs) in 10x Genomics, Inc. (TXG).
- Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting.
- The RSUs vest in equal quarterly installments over one year, beginning May 21, 2026.
- Following this transaction, the director's total beneficial ownership is 37,445 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing regarding standard director compensation.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- None identified; this is a standard equity grant for a board member.
Risks
- Vesting is contingent upon the director continuing to serve as a service provider to the company.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on director equity compensation.
Industry Context
StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology and life sciences sector to ensure director retention and alignment with corporate performance.
Comparison to Industry Standards
- The grant of RSUs to non-employee directors is consistent with compensation practices at peer life sciences companies like Illumina and Pacific Biosciences.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Appointment of Randy Wu and James Bryant as attorneys-in-fact for SEC filings. | 2026-03-05 | Standard administrative procedure to facilitate timely regulatory compliance. |
Stakeholder Impact
- Minimal impact on shareholders; reflects standard board compensation structure.
Next Steps
- Quarterly vesting of RSUs starting from May 21, 2026.
Key Dates
| Date | Description |
|---|---|
| 2026-03-05 | Date of Power of Attorney execution. |
| 2026-05-21 | Start date for RSU vesting measurement. |
| 2026-06-04 | Date of the RSU grant transaction. |
| 2026-06-08 | Date of filing. |
Keywords
10x Genomics, TXG, Director Compensation, Restricted Stock Units, Insider Transaction, SEC Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.